Search

Amphastar Pharmaceuticals Inc

Nyitva

SzektorEgészségügy

21.96 2.04

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

21.22

Maximum

21.74

Fő mutatók

By Trading Economics

Bevétel

24M

30M

Értékesítés

13M

184M

P/E

Szektor átlag

12.343

57.371

Egy részvényre jutó nyereség

0.8

Profit margin

16.502

Munkavállalók

1,976

EBITDA

12M

45M

Ajánlások

By TipRanks

Ajánlások

Semleges

12 hónapos előrejelzés

+3.02% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 5.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

42M

887M

Előző nyitás

19.92

Előző zárás

21.96

Hangulat hírek alapján

By Acuity

50%

50%

150 / 340 Rangsor szerint Healthcare

Amphastar Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 24. 21:01 UTC

Amphastar Pharmaceuticals shares are lower in after-market hours, continuing a five-session decline. No specific news was identified to explain the price movement.

2026. aug. 21. 19:56 UTC

Amphastar Pharmaceuticals Inc shares are lower today, despite earlier fluctuations. No specific news has been identified to explain the price movement.

2026. aug. 20. 19:51 UTC

Amphastar Pharmaceuticals shares are higher, supported by a positive market environment and economic indicators showing strength in the broader economy.

2026. aug. 19. 19:36 UTC

News

Barclays raised its price target on Amphastar Pharmaceuticals to $23.00, contributing to positive sentiment as shares remain well above their 20-day moving average.

2026. aug. 18. 19:16 UTC

Amphastar Pharmaceuticals Inc shares are higher today, reflecting market volatility amid rising U.S. Treasury yields and inflation concerns linked to geopolitical tensions.

2026. aug. 17. 19:16 UTC

Amphastar Pharmaceuticals Inc. shares are lower amid routine market fluctuations and concerns over slowing growth following declines in U.S. retail sales and consumer sentiment.

2026. aug. 14. 20:01 UTC

Amphastar Pharmaceuticals is trading higher, rebounding from an early session low. The stock remains above its 20-day moving average despite no specific news.

2026. aug. 12. 20:06 UTC

Amphastar Pharmaceuticals Inc shares are lower in Wednesday's session, continuing a decline from Tuesday's close amid fluctuating U.S. Treasury yields and inflation data.

2026. aug. 11. 19:56 UTC

News

Amphastar Pharmaceuticals reported Q2 revenue of $183.9 million, exceeding expectations. Shares are modestly higher amid strong demand for key products and new launches.

2026. aug. 10. 19:36 UTC

News

Amphastar Pharmaceuticals reported Q2 earnings of $0.70 per share on $183.9 million in revenue, but shares are trading lower today amid a slight net income decline.

2026. aug. 7. 19:51 UTC

News

Amphastar Pharmaceuticals reported Q2 EPS of $0.91, exceeding estimates. Revenue also surpassed expectations, contributing to a positive market response and higher shares.

2026. aug. 6. 23:02 UTC

News

Amphastar Pharmaceuticals reported second-quarter sales of $183.9 million, exceeding expectations. Shares are trading higher in after-market hours following the strong results.

2026. aug. 4. 19:51 UTC

Amphastar Pharmaceuticals is trading lower today, breaking a trend of higher daily closes. No specific news was identified to explain the decline.

2026. aug. 3. 19:46 UTC

Amphastar Pharmaceuticals Inc is trading higher, reaching a session high amid positive market conditions and falling oil prices influencing investor sentiment.

2026. júl. 31. 19:36 UTC

Amphastar Pharmaceuticals is declining today, continuing a downward trend since Thursday. The stock reached a session low earlier this morning amid broader market volatility.

2026. júl. 30. 19:28 UTC

Amphastar Pharmaceuticals Inc. shares are lower amid significant downward pressure in the Pharmaceuticals sub-sector, reflecting broader sector weakness during Thursday's session.

2026. júl. 29. 20:41 UTC

Amphastar Pharmaceuticals shares are lower in after-market trading, continuing a decline amid rising crude oil prices and geopolitical tensions in the Middle East.

2026. júl. 28. 20:02 UTC

Amphastar Pharmaceuticals shares are higher today, diverging from a broader market decline amid a sell-off in technology stocks across Asian markets.

2026. júl. 24. 19:06 UTC

Amphastar Pharmaceuticals is trading higher, supported by a pullback in crude oil prices, which has eased some inflationary pressures affecting investor sentiment.

2026. júl. 22. 20:06 UTC

Amphastar Pharmaceuticals Inc shares are lower today, continuing a four-session decline amid market uncertainty ahead of the Federal Reserve meeting on July 29.

2026. júl. 21. 19:46 UTC

Amphastar Pharmaceuticals Inc is trading lower, continuing a three-session decline. No specific news was identified to explain the stock's performance.

2026. júl. 20. 19:56 UTC

Amphastar Pharmaceuticals is gaining modestly during Monday's session amid mixed market conditions and geopolitical tensions affecting oil prices and inflation concerns.

Társak összehasonlítása

Árváltozás

Amphastar Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

3.02% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 22.17 USD  3.02%

Magas 30 USD

Alacsony 20 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Amphastar Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Semleges

6 ratings

0

Vétel

5

Tartás

1

Eladás

Hangulat

By Acuity

150 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Neutral

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
help-icon Live chat